Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Locally Advanced Unresectable or Metastatic Solid Tumors 1

Interventions

Specimen Handling 427Magnetic Resonance Spectroscopy 338pembrolizumab 262Biopsy 230Carboplatin 216Cisplatin 180Cyclophosphamide 174Paclitaxel 148Nivolumab 136Gemcitabine 130Radiotherapy 125Dexamethasone 105Bevacizumab 103Radiation 97fludarabine 95Fluorouracil 93Doxorubicin 90Pemetrexed 88Docetaxel 85Rituximab 83durvalumab 82venetoclax 81Oxaliplatin 81Leucovorin 76atezolizumab 70Prednisone 66Lenalidomide 66Capecitabine 66Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
folfirinox × 30 days × Clear all
NCT04589234 2026-05-14

Saltikva for Metastatic Pancreatic Cancer

Salspera LLC

Phase 2 Active not recruiting
60 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05458219 2026-05-04

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
470 enrolled
Other solid neoplasm

Locally Advanced Unresectable or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡